Viropro, Inc. (VPRO)

[LAY01]

Take a look at the potential of Lucanix if future phase 3 clinical are designed correctly.

"Data from a study of 75 patients with advanced stages of lung cancer showed that 43 percent of them were alive two years after receiving NovaRx's drug, dubbed Lucanix. That's four times the survival rate seen with chemotherapy, the current standard of care."

This could become an important treatment in patients with non-small cell lung cancers. The value proposition of this drug might be huge.